TABLE 3.
Pharmacokinetic parameters of meldonium (25 mg/kg) administered by i.v., and i.g., Under acute high-altitude hypoxia.
| PK parameters | Normoxia i.v. | Normoxia i.g. | Hypoxia i.v. | Hypoxia i.g. |
|---|---|---|---|---|
| Administration | Administration | Administration | Administration | |
| Tmax (h) | 0.03 ± 0.00 | 3.00 ± 1.73 | 0.03 ± 0.00 | 4.33 ± 3.14 |
| Cmax (ng/mL) | 79,664.17 ± 13,493.34 | 2,709.92 ± 649.7 | 45,577.47 ± 3,199.05 | 7,321.69 ± 2060.91 a |
| AUCall (h*ng/mL) | 48,999.24 ± 3,131.37 | 17,415.21 ± 3,925.96 | 28,920.63 ± 4,222.44 a | 86,443.85 ± 39,554.66 a |
| Vz/F (mL/kg) | 2,613.66 ± 1,368.78 | 5,335.80 ± 1,286.73 | 4,702.79 ± 1814.47 a | 3,302.48 ± 1,139.24 |
| CL/F (mL/h/kg) | 487.47 ± 34.66 | 1,400.32 ± 362.55 | 743.44 ± 251.94 | 230.76 ± 149.96 a |
| MRTlast (h) | 3.14 ± 0.68 | 4.34 ± 0.58 | 3.43 ± 1.44 | 8.40 ± 1.36 a |
a
Note: p < 0.05 compared to the normoxia group.
Tmax, time taken to attain maximum concentration.
Cmax, Maximum concentration achieved in the blood.
AUCall, area under concentration-time curve for the period from 0 min to infinity time.
Vz/F, the apparent volume of distribution.
CL/F, clearance rate.
MRTlast, last mean residence time.